Boltwood Capital Management decreased its position in Merck & Co., Inc. (NYSE:MRK) by 5.1% during the first quarter, Holdings Channel.com reports. The fund owned 8,239 shares of the company’s stock after selling 444 shares during the quarter. Boltwood Capital Management’s holdings in Merck & Co., Inc. were worth $635,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in MRK. Wealth Alliance increased its position in shares of Merck & Co., Inc. by 9.6% in the third quarter. Wealth Alliance now owns 21,155 shares of the company’s stock valued at $1,755,000 after acquiring an additional 1,845 shares during the period. ExodusPoint Capital Management LP purchased a new position in shares of Merck & Co., Inc. during the third quarter valued at about $1,310,000. OLD Mission Capital LLC purchased a new position in shares of Merck & Co., Inc. during the third quarter valued at about $247,000. First Commonwealth Financial Corp PA increased its position in shares of Merck & Co., Inc. by 5.5% during the third quarter. First Commonwealth Financial Corp PA now owns 4,154 shares of the company’s stock valued at $344,000 after buying an additional 217 shares during the period. Finally, Advisory Alpha LLC purchased a new position in shares of Merck & Co., Inc. during the third quarter valued at about $130,000. Hedge funds and other institutional investors own 72.86% of the company’s stock.
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $95.92.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.06). The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.65 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.16 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, April 7th. Stockholders of record on Monday, March 15th were paid a $0.65 dividend. The ex-dividend date of this dividend was Friday, March 12th. This represents a $2.60 annualized dividend and a dividend yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio is presently 50.10%.
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.
Further Reading: Google Finance Portfolio Workaround
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.